348110-30-5

Basic information

• Product Name: 3-(4-biphenyl)-glutaric acid anhydride
• Synonyms: 3-(4-biphenyl)-glutaric acid anhydride
• CAS NO: 348110-30-5
• Molecular Weight: 266.296
• Mol File: 348110-30-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(4-biphenyl)-glutaric acid anhydride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-biphenyl)-glutaric acid anhydride(348110-30-5)
• EPA Substance Registry System: 3-(4-biphenyl)-glutaric acid anhydride(348110-30-5)

Safety Data

• Hazardous Substances Data: 348110-30-5(Hazardous Substances Data)

Upstream product

• 3218-36-8 4-Phenylbenzaldehyde 
• 101597-48-2 3-(4-biphenyl)-glutaric acid 

Downstream Products

• 1221962-46-4 3-(biphenyl-4-yl)-4-(5-iodo-2-benzimidazolyl)butanoic acid monohydrochloride 
• 1221962-48-6 3-(biphenyl-4-yl)-7-iodo-3,4-dihydropyrido[1,2-a]benzimidazol-1(2H)-one 
• 1221962-49-7 3-(biphenyl-4-yl)-8-iodo-3,4-dihydropyrido[1,2-a]benzimidazol-1(2H)-one 
• 1221962-52-2 3-(biphenyl-4-yl)-7-chloro-3,4-dihydropyrido[1,2-a]benzimidazol-1(2H)-one 
• 1221962-53-3 3-(biphenyl-4-yl)-8-chloro-3,4-dihydropyrido[1,2-a]benzimidazol-1(2H)-one 
• 1221962-51-1 3-(biphenyl-4-yl)-4-(5-chloro-2-benzimidazolyl)-butyramide 
• 1221962-47-5 3-(biphenyl-4-yl)-4-(6-iodo-2-benzimidazolyl)butyramide 
• 348110-37-2 5-[N'-(9H-fluoren-9-ylmethoxycarbonyl)-hydrazino]-5-oxo-3-(4-biphenyl)-pentanoic acid 

Relevant articles and documents

ALLOSTERIC PROTEIN KINASE MODULATORS

The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.

Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective αvβ3 integrin antagonists

The solid-phase synthesis of a low molecular weight RGD mimetic library is described. Activities of the compounds in inhibiting the interaction of ligands, vitronectin and fibrinogen, with isolated immobilized integrins αvβ3 and αIIbβ3 were determined in a screening assay. Highly active and selective nonpeptide αvβ3 integrin antagonists with regard to orally bioavailability were developed, based on the aza-glycine containing lead compound 1. An important variation is the substitution of the aspartic amide of 1 by an aromatic residue. Furthermore, different guanidine mimetics have been incorporated to improve the pharmacokinetic profile. Exchange of the β-amino acid NH by a methylene moiety in one set of RGD mimetics leads to the azacarba analogue compounds representing a novel peptidomimetic approach, which should increase the metabolic stability.